Maternal and perinatal outcome of conservative management of severe preeclampsia in midtrimester

Sibai, Baha M.; Taslimi, M. Mark; Abdella, Thomas N.; Brooks, Todd F.; Spinnato, Joseph A.; Anderson, Garland D.

doi:10.1016/s0002-9378(85)80171-x

Cited by 106 publications

(40 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Abruptio placentae complicates about 4% of cases of severe preeclampsia (4). Neonatal morbidity is most often due to the sequelae of prematurity and low birth weight, including prolonged neonatal intensive care unit stays, respiratory distress, necrotizing enterocolitis, intraventricular hemorrhage, sepsis, and death (5,6). The HELLP syndrome has been associated with a 10 -20% incidence of perinatal mortality, attributable largely to premature delivery (7,8).…”

Section: Clinical Features and Epidemiology Of Preeclampsiamentioning

confidence: 99%

Soluble Fms-like Tyrosine Kinase 1 and Endothelial Dysfunction in the Pathogenesis of Preeclampsia

Venkatesha²,

et al. 2005

View full text Add to dashboard Cite

Section: Clinical Features and Epidemiology Of Preeclampsiamentioning

confidence: 99%

Soluble Fms-like Tyrosine Kinase 1 and Endothelial Dysfunction in the Pathogenesis of Preeclampsia

Venkatesha²,

et al. 2005

View full text Add to dashboard Cite

“…The results of these findings have led to a policy of expectant management to improve neonatal outcome. Expectant management, on the other hand, may worsen maternal condition [4,5]. One randomized trial has shown an improvement of perinatal outcome without deterioration of maternal condition.…”

Section: Introductionmentioning

confidence: 99%

Maternal and Perinatal Outcome During Expectant Management of Severe Pre-Eclampsia Between 24 and 34 Weeks of Gestation

Swamy

Patil

Shailaja

2012

J Obstet Gynecol India

View full text Add to dashboard Cite

Objective To determine the maternal and perinatal outcome after expectant management of severe pre-eclampsia between 24 and 34 weeks of gestation. Method The maternal and fetal status was monitored by an intensive, non-invasive method among 94 women with severe pre-eclampsia between 24 and 34 weeks of gestation who were scheduled for expectant management in the OICU at a tertiary care center. Pregnancy prolongation and maternal and perinatal morbidity and mortality were analyzed by the Student 't' test and the Mann-Whitney U test. Results The days of pregnancy prolongation and perinatal mortality were significantly higher among those managed at \30 weeks. Increasing gestational age correlated with a reduction of RDS. Maternal morbidities were significantly higher among those managed at\28 weeks. But, there was no maternal mortality. Conclusion Expectant management of severe preeclampsia at 30-34 weeks in a tertiary care center of a developing country is associated with good perinatal outcome and risk reduction for the mother.

show abstract

“…It is a major cause of maternal and perinatal morbidity and mortality [1][2][3], with maternal complications like HELLP (haemolysis, elevated liver enzyme levels, low platelet counts) syndrome and eclamptic fits and fetal problems in the form of intra-uterine growth restriction and immaturity from preterm iatrogenic delivery interventions. The general lack of understanding of aetiology and pathophysiology of the condition has undesirably created a major obstacle in the classification and evolution of effective prevention and treatment [4].…”

Section: Introductionmentioning

confidence: 99%

Differential Levels of Interleukin 6 in Maternal and Cord Sera and Placenta in Women with Pre-Eclampsia

Al-Othman¹,

Omu

Diejomaoh

et al. 2001

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: Interleukin 6 (IL-6) is a T helper 2 cytokine with a variety of properties including pro-inflammatory characteristics. It has, therefore, been implicated in the pathophysiology of abnormal pregnancies. Objective: To investigate the association between IL-6 and pre-eclampsia by estimating the differential levels of IL-6 in maternal and cord serum and supernatant of homogenized placental tissue. Methods: 50 primigravidae with pre-eclampsia and 50 matched normotensive primigravidae served as controls. At delivery, maternal and cord blood were collected and the serum extracted. Placental blocks were homogenized and sonicated in RPMI solution and the supernatant collected. The total protein concentration was determined and IL-6 levels assayed with an ELISA technique. Results: Placental IL-6 (170 and 186 pg/mg protein) was threefold that in the maternal (64 and 58 pg/mg protein) and cord serum (63 and 72 pg/mg protein; p < 0.01). There was no significant difference in the mean IL-6 levels in maternal and cord serum or placenta in both pre-eclamptic women and normotensive controls nor in pre-eclamptic patients with babies with intra-uterine growth restriction or in pre-eclamptic patients with babies with an appropriate birth weight and in normotensive controls. Conclusion: There are no differences in the maternal and cord sera and placental levels of IL-6 in pre-eclamptic and normotensive women, indicating that IL-6 may not have a role in the pathophysiology of pre-eclampsia.

show abstract

Maternal and perinatal outcome of conservative management of severe preeclampsia in midtrimester

Cited by 106 publications

References 10 publications

Soluble Fms-like Tyrosine Kinase 1 and Endothelial Dysfunction in the Pathogenesis of Preeclampsia

Soluble Fms-like Tyrosine Kinase 1 and Endothelial Dysfunction in the Pathogenesis of Preeclampsia

Maternal and Perinatal Outcome During Expectant Management of Severe Pre-Eclampsia Between 24 and 34 Weeks of Gestation

Differential Levels of Interleukin 6 in Maternal and Cord Sera and Placenta in Women with Pre-Eclampsia

Contact Info

Product

Resources

About